bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S3 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Authors: Iavarone Claudia , Zervantonakis Ioannis K. , Selfors Laura M. , Palakurthi Sangeetha , Liu Joyce F. , Drapkin Ronny , Matulonis Ursula A. , Hallberg Dorothy , Velculescu Victor E. , Leverson Joel D. , Sampath Deepak , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Supplementary Figure S3 describes the effects of distinct MEK inhibitors in combination with BCL-2/XL inhibition and contribution of BCL-2 vs. BCL-XL to apoptotic vulnerability of HGSOC PDX models
Suppl. Table S5 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Table S5. Detection of HGF in cell supernatants.
Supplementary Figure S2 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Authors: Iavarone Claudia , Zervantonakis Ioannis K. , Selfors Laura M. , Palakurthi Sangeetha , Liu Joyce F. , Drapkin Ronny , Matulonis Ursula A. , Hallberg Dorothy , Velculescu Victor E. , Leverson Joel D. , Sampath Deepak , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Supplementary Figure S2 describes the effects of MEK inhibition on cell proliferation and BCL-2 family protein levels.
Suppl. Table S4 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Table S4. Sensitivity of emibetuzumab-resistant cell lines to various TKIs compared with SNU-5 cells.
Supplementary Figure S1 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Authors: Iavarone Claudia , Zervantonakis Ioannis K. , Selfors Laura M. , Palakurthi Sangeetha , Liu Joyce F. , Drapkin Ronny , Matulonis Ursula A. , Hallberg Dorothy , Velculescu Victor E. , Leverson Joel D. , Sampath Deepak , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Supplementary Figure 1 shows the analysis of MEK/ERK pathway activation in HGSOC PDX models
Suppl. Table S3 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Table S3. Limma output from comparison of 4626 with parental SNU-5 cells treated with emibetuzumab.
Suppl. Table S2 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Table S2. Limma output from comparison of 7333 with parental SNU-5 cells treated with emibetuzumab.
Supplementary Figures S1 - S7 & Supplementary Table S1 from SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules
Authors: Wang Fang , Zheng Li , Yi Yuyao , Yang Zhuang , Qiu Qiang , Wang Xiaoyan , Yan Wei , Bai Peng , Yang Jianhong , Li Dan , Pei Heying , Niu Ting , Ye Haoyu , Nie Chunlai , Hu Yiguo , Yang Shengyong , Wei Yuquan , Chen Lijuan
Published: April 2023

Figure S1: A, HDAC6 activity assay of the cell lines. B, The quantified relative expression level of Ac- ÃŽÂ±-tubulin and Ac-H3 in the cell lines effected by the HDAC inhibitors. Figure S2: Clonogenic formation potential of HDAC6 knock out cell lines compared to parent cell lines. Figure S3: Morphological analysis of the cellular microtubule network and Ac-ÃŽÂ±-tubulin by immunofluorescence staining. Figure S4: Effects of ACY1215 on cell cycle in A2780s cells. Figure S5: Effects of SKLB-23bb on the intrinsic apoptosis pathway. Figure S6: SKLB-23bb exhibited superior anti-tumor activity in B cell lymphoma HBL-1 xenografts. Figure S7: The quantified relative expression level of Ac- ÃŽÂ±-tubulin, Ac-H3 and p-H3 in the hct116 xenograft tissues post SKLB-23bb single dose. Table S1: Summary of the anti-tumor activity of SKLB-23BB compared to ACY1215 against HBL-1 xenograft.
Suppl. Fig. S1-7 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Figure S1. Sequence homology to human and mouse reference genomes. Supplementary Figure S2. No SNU-5 tumors establish upon continuous treatment with emibetuzumab Supplementary Figure S3. MET level in 7333 and with or without emibetuzumab treatment. Supplementary Figure S4. Log2 ratios for MYC, PVT1, and ERBB3 copy number gains in the 4626 tumor. Supplementary Figure S5. HER3 level in SNU-5 cell lines. Supplementary Figure S6. Both emibetuzumab-resistant cell lines are resistant to Sym015 in vitro. Supplementary Figure S7. SNU-5 are equally sensitive to Sym015 and Sym015 LALA in vivo.
Supplemental Figures 1-4 from AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
Authors: Liu Chengfei , Yang Joy C. , Armstrong Cameron M. , Lou Wei , Liu Liangren , Qiu Xiaomin , Zou Binhao , Lombard Alan P. , D'Abronzo Leandro S. , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplemental Figure 1: C4-2B parental and C4-2B MDVR tumors were processed and whole tumor lysates were extracted and subjected to western blot; Supplemental Figure 2: The KLK3 mRNA expression and PSA expression in C4-2B parental and C4-2B MDVR cells were determined by qRT-PCR and PSA ELISA respectively; Supplemental Figure 3: Eight C4-2B AKR1C3 stable clones were picked and whole cell lysates were extracted and subjected to western blot; Supplemental Figure 4: AR-V7 was knocked down in LNCaP-neo cells, cells were then treated with 20 µM enzalutamide for 5 days and total cell number was determined.
Supplemental Figure 2 from STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
Authors: Njatcha Christian , Farooqui Mariya , Kornberg Adam , Johnson Daniel E. , Grandis Jennifer R. , Siegfried Jill M.
Published: April 2023

Specificity of STAT3 decoy on gene regulation
Figure S4 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Dot plots for the xenograft experiment
Supplementary Table S4 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

Clinical signs score sheet for health assessment
Supplementary Table S3 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

Description of antibodies used for protein detection
Supplementary Table S2 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

General characteristics and genetic profile of cell lines
Figure S1 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Chemical structure of indolocarbazoles EC-70124 and midostaurin (PKC-412)
Supplementary Table S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

Potency of BOS172722 alone, Paclitaxel alone and in combination in TNBC cell lines.
Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

Horizon PTEN +/- cell line panel and Enrichment of mutated genes in cell lines sensitive to BOS172722
Supplementary Materials and Methods from ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models
Authors: Li Yingchun , Hickson Jonathan A. , Ambrosi Dominic J. , Haasch Deanna L. , Foster-Duke Kelly D. , Eaton Lucia J. , DiGiammarino Enrico L. , Panchal Sanjay C. , Jiang Fang , Mudd Sarah R. , Zhang Catherine , Akella Surekha S. , Gao Wenqing , Ralston Sherry L. , Naumovski Louie , Gu Jijie , Morgan-Lappe Susan E.
Published: April 2023

This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 and VEGF in cynomolgus monkey plasma.
Supplementary Figure S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

In vivo efficacy of BOS172722 in MDA-MB-231 tumour bearing mice.
Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

Cellular activity of BOS172722
Supplementary Table S2 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Expression of NF-κB and p-NF-κB in bladder tissue microarrays.
Supplementary Figure S1 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Relationship between the expression levels of NF-κB/p65 versus p-NF-κB/p65 (A), AR versus NF-κB/p65 (B), and AR versus p-NF-κB/p65 (C) in bladder tumor specimens. Scatter plots show the distribution of IHC scores (0/1+/2+/3+) of two proteins. The Spearman's correlation coefficient (CC) and P value are indicated in each dot plot.
Supplementary Table S1 from PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells
Authors: Cai Wangyu , Chen Gang , Luo Qicong , Liu Jun , Guo Xiaofeng , Zhang Tian , Ma Fei , Yuan Liang , Li Boan , Cai Jianchun
Published: April 2023

The protein expression profiles of the third passage DDP treated xenografts versus the 0.9% NaCl treated controls.
Table S2 from Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
Authors: Lau Wen Min , Teng Eileen , Huang Kie Kyon , Tan Jin Wei , Das Kakoli , Zang Zhijiang , Chia Tania , Teh Ming , Kono Koji , Yong Wei Peng , Shabbir Asim , Tay Amy , Phua Niam Sin , Tan Patrick , Chan Shing Leng , So Jimmy Bok Yan
Published: April 2023

Gene variations in GAGA samples Single
Supplementary Figures S1-S4 and Supplementary Methods from A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
Authors: Du Jie , Shang Jun , Chen Fei , Zhang Yushuo , Yin Narui , Xie Ting , Zhang Haowen , Yu Jiahua , Liu Fenju
Published: April 2023

Figure S1: HRM analysis of the sgHBEGF-induced mutation; Figure S2: Figure S3: Selected hits of NHEJ inhibitors; Figure S4: The direct effects of ouabain and penfluridol on DNA-PK were examined by using DNA-PK activity assayin vitro.
Supplementary Figures 1-4 from Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer
Authors: Kim Bo Ram , Jeong Yoon A. , Jo Min Jee , Park Seong Hye , Na Yoo Jin , Kim Jung Lim , Jeong Soyeon , Yun Hye Kyeong , Kang Sanghee , Lee Dae-Hee , Oh Sang Cheul
Published: April 2023

Supplementary Fig. 1. Genipin enhanced oxaliplatin sensitivity, but not geniposide in HCT116. Supplementary Fig. 2. Genipin increased oxaliplatin-induced apoptosis in DLD-1. Supplementary Fig. 3. Genipin induced the activation of the ROS-ER stress-JNK pathway. Supplemental Fig. 4 Combination of oxaliplatin and genipin decreased tumor growth in vivo.
Figure S2 from Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
Authors: Lau Wen Min , Teng Eileen , Huang Kie Kyon , Tan Jin Wei , Das Kakoli , Zang Zhijiang , Chia Tania , Teh Ming , Kono Koji , Yong Wei Peng , Shabbir Asim , Tay Amy , Phua Niam Sin , Tan Patrick , Chan Shing Leng , So Jimmy Bok Yan
Published: April 2023

AZD4547 treatment and downstream analysis in GAGA3 and GAGA6 PDX models.
Figure S1 from Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
Authors: Lau Wen Min , Teng Eileen , Huang Kie Kyon , Tan Jin Wei , Das Kakoli , Zang Zhijiang , Chia Tania , Teh Ming , Kono Koji , Yong Wei Peng , Shabbir Asim , Tay Amy , Phua Niam Sin , Tan Patrick , Chan Shing Leng , So Jimmy Bok Yan
Published: April 2023

Comparison of histology and copy number variations of GAGA1, GAGA3 and GAGA6 primary tumors and PDX models
Figure S4 from Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Authors: Harada Takeshi , Matsumoto Shinji , Hirota Suguru , Kimura Hirokazu , Fujii Shinsuke , Kasahara Yuuya , Gon Hidetoshi , Yoshida Toshihiko , Itoh Tomoo , Haraguchi Naotsugu , Mizushima Tsunekazu , Noda Takehiro , Eguchi Hidetoshi , Nojima Satoshi , Morii Eiichi , Fukumoto Takumi , Obika Satoshi , Kikuchi Akira
Published: April 2023

PIK3CD is a downstream target of ARL4C in HCC cells.
Figure S3 from Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Authors: Harada Takeshi , Matsumoto Shinji , Hirota Suguru , Kimura Hirokazu , Fujii Shinsuke , Kasahara Yuuya , Gon Hidetoshi , Yoshida Toshihiko , Itoh Tomoo , Haraguchi Naotsugu , Mizushima Tsunekazu , Noda Takehiro , Eguchi Hidetoshi , Nojima Satoshi , Morii Eiichi , Fukumoto Takumi , Obika Satoshi , Kikuchi Akira
Published: April 2023

YAP/TAZ is not a downstream target of ARL4C in HCC cells.
Figure S2 from Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Authors: Harada Takeshi , Matsumoto Shinji , Hirota Suguru , Kimura Hirokazu , Fujii Shinsuke , Kasahara Yuuya , Gon Hidetoshi , Yoshida Toshihiko , Itoh Tomoo , Haraguchi Naotsugu , Mizushima Tsunekazu , Noda Takehiro , Eguchi Hidetoshi , Nojima Satoshi , Morii Eiichi , Fukumoto Takumi , Obika Satoshi , Kikuchi Akira
Published: April 2023

ASOs suppress ARL4C mRNA expression in vitro.
Table S3 from Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer
Authors: Hsu Hung-Chih , Lapke Nina , Wang Chuang-Wei , Lin Pei-Yi , You Jeng Fu , Yeh Chien Yuh , Tsai Wen-Sy , Hung Hsin Yuan , Chiang Sum-Fu , Chen Hua-Chien , Chen Shu-Jen , Hsu An , Yang Tsai Sheng
Published: April 2023

Clinical data and sample details of 18 follow-up patients include in the study
Figure S2 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

HER3 expression in representative colorectal cell lines
Table S1 from Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer
Authors: Hsu Hung-Chih , Lapke Nina , Wang Chuang-Wei , Lin Pei-Yi , You Jeng Fu , Yeh Chien Yuh , Tsai Wen-Sy , Hung Hsin Yuan , Chiang Sum-Fu , Chen Hua-Chien , Chen Shu-Jen , Hsu An , Yang Tsai Sheng
Published: April 2023

Hotspots included in the 12 gene NGS panel used in this study
Table S1 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

Summary of IC50 and copy number of JHDM1D and BRAF in parental cells and AZD-R clones.
Figure S6 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

Cell growth inhibition by RAF inhibitors in AZD-R clones.
Figure S4 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Authors: Min Ahrum , Jang Hyemin , Kim Seongyeong , Lee Kyung-Hun , Kim Debora Keunyoung , Suh Koung Jin , Yang Yaewon , Elvin Paul , O'Connor Mark J. , Im Seock-Ah
Published: April 2023

TOPORS expression determined the combined effects of AZD3514 and olaparib
Figure S2 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Authors: Min Ahrum , Jang Hyemin , Kim Seongyeong , Lee Kyung-Hun , Kim Debora Keunyoung , Suh Koung Jin , Yang Yaewon , Elvin Paul , O'Connor Mark J. , Im Seock-Ah
Published: April 2023

Anti-proliferative effects of AR inhibition using AZD3514 on human breast cancer cells
Figure S2 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

No feedback activation of FGFR2 by CH4987655 in AZD-R Clone 1.
Figure S8 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S8 shows the flow cytometric analysis from control and drug treated mice.
Figure S7 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S7 shows that Galunisertib and anti-PD-1 dual treatment promotes GranzymeB production in tumor infiltrating cytotoxic T lymphocytes.
Figure S5 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S5 shows additional H&E stained sections from Galunisertib and/or anti-PD-1 treated mice.
Figure S4 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S4 shows gross changes in tissue architecture, length, and weight in control and Galunisertib/anti-PD-1 treated mice.
Supplementary Figures 1-3 and Table1 from Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies
Authors: Tintelnot Joseph , Baum Natalie , Schultheiß Christoph , Braig Friederike , Trentmann Marie , Finter Johannes , Fumey William , Bannas Peter , Fehse Boris , Riecken Kristoffer , Schuetze Kerstin , Bokemeyer Carsten , Rösner Thies , Valerius Thomas , Peipp Matthias , Koch-Nolte Friedrich , Binder Mascha
Published: April 2023

Supplementary Figure 1 shows Nanobody 7D12 block of different EGFR ligands; Supplementary Figure 2 shows EGFR expression and EGF stimulated growth of mutated EGFR variants; Supplementary Figure 3 shows phage display experiments; Supplementary Table 1 shows EGFR primers.
Supplementary Tables and Figures from Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates
Authors: Neumann Christopher S. , Olivas Kathleen C. , Anderson Martha E. , Cochran Julia H. , Jin Steven , Li Fu , Loftus Luke V. , Meyer David W. , Neale Jason , Nix Jay C. , Pittman Paul G. , Simmons Jessica K. , Ulrich Michelle L. , Waight Andrew B. , Wong Abbie , Zaval Margo C. , Zeng Weiping , Lyon Robert P. , Senter Peter D.
Published: April 2023

Supplemental tables and figures referenced in main text: Table S1 - Crystallography data collection and refinement statistics; Table S2 - ADC characterization data; Figure S1 - ADC plasma stability data; Figure S2 - Time course for ADC activity in vitro; Table S3 - additional in vitro potency data for ADCs targeting CD30, CD19, and CD123.
Figure S2 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S2 shows the expression of PD-L1 in a cohort of pancreatic cancer patients.
Supplementary Tables S1-S2 and Supplementary Figures S1-S6 from Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors
Authors: Srivastava Apurva K. , Hollingshead Melinda G. , Govindharajulu Jeevan Prasaad , Covey Joseph M. , Liston Dane , Simpson Melanie A. , Peggins James O. , Bottaro Donald P. , Wright John J. , Kinders Robert J. , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains Supplementary Tables S1 and S2 (pharmacokinetic data) and Supplementary Figures S1 (chemical structures of the four MET kinase inhibitors examined in this study), S2 (pharmacokinetic and pharmacodynamic data for ARQ197), S3 (body weight data for pharmacodynamics-guided dosage regimens), S4 (total full-length MET levels in the single-dose, dose-response time course experiment), S5 (total full-length MET levels in single- and multi-dose experiments using the pharmacodynamics-guided dosage regimens), and S6 (mouse tolerability information for XL880, XL184, and EMD1214063).
Supplementary methods from Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Authors: Zaman Saif , Yu Xin , Bencivenga Anthony F. , Blanden Adam R. , Liu Yue , Withers Tracy , Na Bing , Blayney Alan J. , Gilleran John , Boothman David A. , Loh Stewart N. , Kimball S. David , Carpizo Darren R.
Published: April 2023

Suppl. Methods included the methods used in the paper, Cell growth inhibition assay, Immunofluorescent staining, Synthesis of ZMC1, Synthesis of 2,2'-((2-Ethoxy-2-oxoethyl)azanediyl)diacetic acid (NTA-MEE) and NTA-DEE, Zn2+-Kd measurements by competition, Metal binding experiments, Colony formation assays, Oxidative stress detection, Apoptosis assay (Annexin V staining).
Supplementary Figures S1-S10 from Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Authors: Zaman Saif , Yu Xin , Bencivenga Anthony F. , Blanden Adam R. , Liu Yue , Withers Tracy , Na Bing , Blayney Alan J. , Gilleran John , Boothman David A. , Loh Stewart N. , Kimball S. David , Carpizo Darren R.
Published: April 2023

Suppl. Fig. S1 display ZMC1 structure. Suppl. Fig. S2 showed no synergy in combination treatment of ZMC1 and Adriamycin or IR. Suppl. Fig. S3 showed synergy in Detroit 562 cells by combination treatment of ZMC1 and Irinotecan in the presence of GSH. Suppl. Fig. S4 showed combination response of ZMC1 and DNA damaging reagent (Irinotecan) in the presence of GSH. Suppl. Fig. S5 showed combination response to ZMC1 and Etoposide is mutant p53 dependent. Suppl. Fig. S6 showed measurement of KCuZMC1 using EGTA competition assay. Suppl. Fig. S7 displayed NTA competition assay for determining KCuC12. Suppl. Fig. S8 showed combination response to MEE or DEE and Etoposide is mutant p53 dependent. Suppl. Fig. S9 showed 5 combination treatments of ZMC1 and other targeted therapy drugs (A) b-Lapachone (b-Lap), (B) ThioNa, (C) 6-AN, (D) ABT-199, (E) Nutlin 3a. Suppl. Fig. S10 showed that the combination treatment of ZMC1 and ABT-199 promoted more apoptosis.
Figure S2 from Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model
Authors: MacFarland Suzanne P. , Naraparaju Koumudi , Iyer Radhika , Guan Peng , Kolla Venkatadri , Hu Yuxuan , Tan Kai , Brodeur Garrett M.
Published: April 2023

Figure 1 densiometry including error bars and asterisks to indicate statistical significance (alpha <0.05)
Supplementary Table S1 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Quantified target bands from Figure 2
Supplementary Figure 5 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

ERBB3 levels are significantly higher following co-treatment with letrozole and everolimus
Supplementary Figure 3 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Pharmacodynamic analyses of HRG and ERBB3 expression in tumors harvested post-treatment
Supplementary Figure 2 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Statistical analyses of tumor growth curves in mouse study 1 (Figure 3)
Supplementary Figure 1 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Heregulin is expressed in MCF-7Ca and LTLT-Ca cells
Figure S4 from HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
Authors: Proia David A. , Smith Donald L. , Zhang Junyi , Jimenez John-Paul , Sang Jim , Ogawa Luisa Shin , Sequeira Manuel , Acquaviva Jaime , He Suqin , Zhang Chaohua , Khazak Vladimir , Astsaturov Igor , Inoue Takayo , Tatsuta Noriaki , Osman Sami , Bates Richard C. , Chimmanamada Dinesh , Ying Weiwen
Published: April 2023

γ-H2AX expression analysis in MDA-MB-231 xenografts following STA-12-8663 treatment.
Supplementary Figures 1-5, Supplementary Tables 1-2 from Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles
Authors: Das Sreemanti , Mukherjee Pritha , Chatterjee Ranodeep , Jamal Zarqua , Chatterji Urmi
Published: April 2023

Figure S1: Drug release kinetics in mouse plasma. Figure S2: Cell viability assay. Figure S3: Western blot analysis. Figure S4: Effect of Wdl and nWdl on solid tumors in mice. Figure S5: Retention of nanoparticle in mice tumor and liver. Supplementary Table 1: List of primers used in qRT-PCR experiments. Supplementary Table 2: Hematology of normal, EAC, wedelolactone (Wdl) treated and nano-wedelolactone (nWdl) treated mice. Impact on Hb, RBC, WBC, neutrophil%, lymphocyte%, monocyte%,eosinophil% has been recorded.
Supplementary Figure legends from Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Authors: Davies Barry R. , Guan Nin , Logie Armelle , Crafter Claire , Hanson Lyndsey , Jacobs Vivien , James Neil , Dudley Philippa , Jacques Kelly , Ladd Brendon , D'Cruz Celina M. , Zinda Michael , Lindemann Justin , Kodaira Makoto , Tamura Kenji , Jenkins Emma L.
Published: April 2023

This file contains the supplementary figure legends
Supplementary Data from Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs
Authors: Wang Yongqiang , Huang Zenghong , Chen Christopher Z. , Liu Chengfei , Evans Christopher P. , Gao Allen C. , Zhou Fangjian , Chen Hong-Wu
Published: April 2023

Supplementary Figures and Tables
Supplementary Figure S1 from The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6
Authors: Cai Jian , Wang Huaiming , Jiao Xiaodong , Huang Rongkang , Qin Qiyuan , Zhang Jianwei , Chen Honglei , Feng Dan , Tian Xin , Wang Hui
Published: April 2023

TMA-HuR expression by IHC.
Table S1 from Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
Authors: Berndt-Paetz Mandy , Schulze Philipp , Stenglein Philipp C. , Weimann Annett , Wang Qiang , Horn Lars-Christian , Riyad Yasser M. , Griebel Jan , Hermann Ralf , Glasow Annegret , Stolzenburg Jens-Uwe , Neuhaus Jochen
Published: April 2023

Table S1 shows current bladder Tumor classification (modified to our needs).
Figure S5 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

In vitro non-target mediated CH129-ADC cytotoxicity on the antigen-negative AGS cells
Table S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Authors: Mao Fengyi , Li Jie , Luo Qian , Wang Ruixin , Kong Yifan , Carlock Colin , Liu Zian , Elzey Bennet D. , Liu Xiaoqi
Published: April 2023

IC50 of C4-2 cells
Figure S4 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

Effective cellular internalization and immune effector functions by FG129
Figure S4 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Authors: Mao Fengyi , Li Jie , Luo Qian , Wang Ruixin , Kong Yifan , Carlock Colin , Liu Zian , Elzey Bennet D. , Liu Xiaoqi
Published: April 2023

Co-treatment with GSK461364A and JQ1 has a minor impact on PD-L1 expression
Supplemental Figure 3 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Authors: Lemberg Kathryn M. , Zhao Liang , Wu Ying , Veeravalli Vijayabhaskar , Alt Jesse , Aguilar Joanna Marie H. , Dash Ranjeet P. , Lam Jenny , Tenora Lukáš , Rodriguez Chabely , Nedelcovych Michael T. , Brayton Cory , Majer Pavel , Blakeley Jaishri O. , Rais Rana , Slusher Barbara S.
Published: April 2023

Supplemental Figure 3: Ex vivo JHU395 vs vehicle treated tumor histological analyses and plasma glutamine from non-tumored mice
Supplementary Fig. S3 from A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment
Authors: Zhang Limin , Pattanayak Abhinandan , Li Wenqi , Ko Hyun-Kyung , Fowler Graham , Gordon Ryan , Bergan Raymond
Published: April 2023

Supplementary Fig. S3 shows that PC3-M-luc cells can be quantified in mouse lung by qPCR
Supplementary Fig. S2 from A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment
Authors: Zhang Limin , Pattanayak Abhinandan , Li Wenqi , Ko Hyun-Kyung , Fowler Graham , Gordon Ryan , Bergan Raymond
Published: April 2023

Supplementary Fig. S2 shows that docetaxel inhibits human prostate cancer growth in mice in a dose-responsive fashion
Supplementary Tables S1-S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Table S1. Commercial tumor TMAs representing different solid tumor types. Supplementary Table S2. Summary of CD205 expression in human solid tumor types.
Supplementary Table S3 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Table S3: Cross reactivity data obtained from whole blood of different species. Values are expressed as the concentration at which MBH1309/OBT076 has half-maximum binding [EC50].
Supplementary Figure S2 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for VEGFC mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
Supplemental figure legends from Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
Authors: Ono Yoshihiro Joshua , Tanabe Akiko , Tanaka Tomohito , Tanaka Yoshimichi , Hayashi Masami , Terai Yoshito , Ohmichi Masahide
Published: April 2023

Figure legends of supplemental figure 1 - 5.
Supplemental figure 5 from Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
Authors: Ono Yoshihiro Joshua , Tanabe Akiko , Tanaka Tomohito , Tanaka Yoshimichi , Hayashi Masami , Terai Yoshito , Ohmichi Masahide
Published: April 2023

Expression of CD24, phospho-Met, MDR-1 and MRP in cisplatin-treated EC xenogrft tumors
Supplemental figure 3 from Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
Authors: Ono Yoshihiro Joshua , Tanabe Akiko , Tanaka Tomohito , Tanaka Yoshimichi , Hayashi Masami , Terai Yoshito , Ohmichi Masahide
Published: April 2023

Confirmation of CD24 overexpression in CD24 DNA construct transfected cells
Supplemental figure 2 from Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
Authors: Ono Yoshihiro Joshua , Tanabe Akiko , Tanaka Tomohito , Tanaka Yoshimichi , Hayashi Masami , Terai Yoshito , Ohmichi Masahide
Published: April 2023

CD24 knocked down EC cells are more cisplatin-resistant
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Authors: Villar-Prados Alejandro , Wu Sherry Y. , Court Karem A. , Ma Shaolin , LaFargue Christopher , Chowdhury Mamur A. , Engelhardt Margaret I. , Ivan Cristina , Ram Prahlad T. , Wang Ying , Baggerly Keith , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Yang Shyh-Ming , Maloney David J. , Yoshioka Makoto , Strovel Jeffrey W. , Roszik Jason , Sood Anil K.
Published: April 2023

Raw RPPA data for OVCAR 4.
Supplementary Figure S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Authors: Brünker Peter , Wartha Katharina , Friess Thomas , Grau-Richards Sandra , Waldhauer Inja , Koller Claudia Ferrara , Weiser Barbara , Majety Meher , Runza Valeria , Niu Huifeng , Packman Kathryn , Feng Ningping , Daouti Sherif , Hosse Ralf J. , Mössner Ekkehard , Weber Thomas G. , Herting Frank , Scheuer Werner , Sade Hadassah , Shao Cuiying , Liu Bin , Wang Peng , Xu Gary , Vega-Harring Suzana , Klein Christian , Bosslet Klaus , Umaña Pablo
Published: April 2023

FAP-drozitumab BsAb induces tumor growth inhibition in vivo.
Supplemental Figure Legends from Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Beggs Reena R. , Cooper Tiffiny S. , Weaver Alice N. , Yang Eddy S.
Published: April 2023

Figure legends for supplemental figures
Supplemental Figure 2 from Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Beggs Reena R. , Cooper Tiffiny S. , Weaver Alice N. , Yang Eddy S.
Published: April 2023

Supplemental Figure S2. Cell cycle analysis in prexasertib treated UM-SCC1 cells in the presence or absence of serum
Supplementary Figure 5 from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

Analyses of tumor microenvironment in the 1411HP and A2780cis tumor model.
Supplementary Figures S1-S4 from Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression
Authors: Garton Andrew J. , Seibel Scott , Lopresti-Morrow Lori , Crew Linda , Janson Neal , Mandiyan Sreekala , Trombetta E. Sergio , Pankratz Shannon , LaVallee Theresa M. , Gedrich Richard
Published: April 2023

Supplemental Figure S1A - Gating Plot Example for Identification of MDSC Populations in Spleen Samples (Pan02 Study); Supplemental Figure S1B - Gating Plot Example for Identification of T-Cell Populations in Tumor Samples (Pan02 Study); Supplemental Figure S2 - Inhibition of Mammalian KIT by KTN0158; Supplemental Figure S3 - Growth of Colon26 Tumor Cells In Vitro is SCF/KIT-Signaling Independent; Supplemental Figure S4 - Individual Tumor Growth Curves from the Colon26 Efficacy Study.
Supplementary Figure 4 from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

pH dependent development of cytotoxicity (SRB-assay) of the copolymer-Dox conjugate in 1411HP and A2780cis cells.
Supplementary Figure S1. Plasma stability from Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Setter Jocelyn R. , Hunter Joshua H. , Cochran Julia H. , Waight Andrew B. , Gordon Kristine A. , Toki Brian E. , Emmerton Kim K. , Zeng Weiping , Stone Ivan J. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

Plasma stability of quaternary ammonium linker in rodent plasma.
Supplementary Figure 1 from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

Analyses of tumor response to treatment with Dox and different doses of pHPMA-Dox conjugate in the A2780cis tumor model.
Chemistry Experimental from Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Setter Jocelyn R. , Hunter Joshua H. , Cochran Julia H. , Waight Andrew B. , Gordon Kristine A. , Toki Brian E. , Emmerton Kim K. , Zeng Weiping , Stone Ivan J. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

Experimental details for the chemical synthesis of the drug-linkers.
Supplementary data: Figures 1-6; Tables 1 and 2 from A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
Authors: Xiao Zhan , Carrasco Rosa A. , Schifferli Kevin , Kinneer Krista , Tammali Ravinder , Chen Hong , Rothstein Ray , Wetzel Leslie , Yang Chunning , Chowdhury Partha , Tsui Ping , Steiner Philipp , Jallal Bahija , Herbst Ronald , Hollingsworth Robert E. , Tice David A.
Published: April 2023

Figure 1: KTN3379 specifically binds to HER3; Figure 2: KTN3379 suppresses cell-growth in HRG-HER3 autocrine cells and HRGinduced VEGF secretion; Figure 3: KTN3379 arrests HER2+ breast cancer cells in G0/G1-phase; Figure 4: KTN3379 is inactive in HER3-positive but HRG-negative Snu16 xenograft model; Figure 5: PTEN knockdown does not impact the growth behavior of HMCB; Figure 6: Full dose response curves of KTN3379, Pertuzumab and Cetuximab in HMCB cells with or without PTEN-knockout in 6-day proliferation assay; Supplementary Table 1 Summary of Kinetic Rate Constants and Dissociation Constants for the Binding of KTN3379 to Human HER3, Cynomolgus Monkey HER3, and Murine Her3 Proteins; Supplementary Table 2 Expression and mutation status of HER3 pathway components of models used in this manuscript
Supplementary data from A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
Authors: Xiao Zhan , Carrasco Rosa A. , Schifferli Kevin , Kinneer Krista , Tammali Ravinder , Chen Hong , Rothstein Ray , Wetzel Leslie , Yang Chunning , Chowdhury Partha , Tsui Ping , Steiner Philipp , Jallal Bahija , Herbst Ronald , Hollingsworth Robert E. , Tice David A.
Published: April 2023

Methods and figure legends for supplemental data
Supplementary Data from miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma
Authors: Shao Naiyuan , Xue Lian , Wang Rong , Luo Kaiming , Zhi Feng , Lan Qing
Published: April 2023

Supplementary Table 1. Univariate and multivariate analyses on survival in glioma patients. Supplementary Figure 1: Real-time PCR analysis of exosomal miR-454-3p in the serum of glioma patients and that of healthy controls in the combination group. Supplementary Figure 2: ATG12 is highly expressed in glioma. (A) ATG12 expression in different types of cancer and in their respective normal controls on GEPIA. GBM: glioblastoma, LLG: low grade glioma. (B) ATG12 expression in GBM and non-tumor on Gliovis. GBM: glioblastoma.